Last C$0.42 CAD
Change Today -0.02 / -4.55%
Volume 7.5K
DMA On Other Exchanges
As of 12:15 PM 09/22/14 All times are local (Market data is delayed by at least 15 minutes).

diamedica inc (DMA) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/23/13 - C$1.40
52 Week Low
09/11/14 - C$0.36
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DIAMEDICA INC (DMA)

Related News

No related news articles were found.

diamedica inc (DMA) Related Businessweek News

No Related Businessweek News Found

diamedica inc (DMA) Details

DiaMedica Inc., a development stage biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. The company’s lead clinical stage compound is DM199, a recombinant human protein known as rhKLK1, which is under phase I/II clinical trials for the treatment of Type 1 and Type 2 diabetes and associated complications. It is also developing DM204, a monoclonal antibody that is in preclinical development for the treatment of Type 2 diabetes; and DMDx, a chronic kidney disease assay to detect levels of the tissue kallikrein-1 protein in urine and to predict the rate of kidney disease progression. The company was formerly known as Diabex Inc. and changed its name to DiaMedica Inc. in February 2001. DiaMedica Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Founded in 2000

diamedica inc (DMA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$276.5K
Chief Financial Officer
Total Annual Compensation: --
Executive Vice President
Total Annual Compensation: C$234.0K
Vice-President of Research
Total Annual Compensation: C$177.0K
Vice President of Finance
Total Annual Compensation: C$74.5K
Compensation as of Fiscal Year 2013.

diamedica inc (DMA) Key Developments

Diamedica Inc. Approves Amendments to the Articles of Incorporation and By-Laws

Diamedica Inc. at its annual general and special meeting of shareholders held on July 24, 2014 approved to amend the Articles of Incorporation to consolidate the outstanding common shares on the basis of one post-consolidation common share for each two to ten pre-consolidation common shares; and approved certain amendments to the company's by-laws; and renewing the shareholder rights plan of the company.

Diamedica Inc. Presents at 3rd Annual InvestMNt Conference, Aug-06-2014 03:45 PM

Diamedica Inc. Presents at 3rd Annual InvestMNt Conference, Aug-06-2014 03:45 PM. Venue: University of St. Thomas Corporate Room Block, 1101 LaSalle Avenue, Minneapolis, MN 55403, United States.

DiaMedica Inc. Promotes Mark Robbins to Executive Vice President

DiaMedica Inc. announced the promotion of Mark Robbins, Ph.D., J.D., to Executive Vice President. Dr. Robbins joined DiaMedica in December 2012 as Vice President, Clinical and Regulatory Affairs. He will continue to oversee the Company's clinical development efforts. Prior to joining DiaMedica, Dr. Robbins spent 15 years with Upsher-Smith Laboratories, advancing to Executive Vice President, Legal, Scientific and Technical Operations, Chief Scientific Officer and Assistant Secretary, where he oversaw the clinical and regulatory strategies for several drugs ranging from R&D to manufacturing and Phase I to Phase III.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DMA:CN C$0.42 CAD -0.02

DMA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DMA.
View Industry Companies

Industry Analysis


Industry Average

Valuation DMA Industry Range
No financial data is available for DMA.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DIAMEDICA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at